Gene · 6752
SSTR2: somatostatin receptor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SSTR2: somatostatin receptor 2. Genes, record 6752. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6752
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P30874 | Somatostatin receptor type 2 | 369 | 17 | Ensembl, GeneID, HGNC |
Source UniProt
Patents96
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 52 | P30874 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 4456 | P30874 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 4456 | P30874 | Espacenet |
| JP 2025515134 A | 2025-05-13 | 55 | P30874 | Espacenet |
| JP 2025515134 A | 2025-05-13 | 70 | P30874 | Espacenet |
| EP 4519294 A1 | 2025-03-12 | 55 | P30874 | Espacenet |
| EP 4519294 A1 | 2025-03-12 | 70 | P30874 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 36507 | P30874 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 36507 | P30874 | Espacenet |
| US 12121590 B2 | 2024-10-22 | 121 | P30874 | Espacenet |
1 to 10 of 96
See all 96 patentsDrugs14
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| LANREOTIDE | CHEMBL1201185 | Somatostatin receptor 2 agonist | AGONIST | ChEMBL |
| LANREOTIDE ACETATE | CHEMBL1201184 | Somatostatin receptor 2 agonist | AGONIST | ChEMBL |
| LUTETIUM OXODOTREOTIDE | CHEMBL4302409 | Somatostatin receptor binding agent | BINDING AGENT | ChEMBL |
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Somatostatin receptor binding agent | BINDING AGENT | ChEMBL |
| OCTREOTIDE | CHEMBL1680 | Somatostatin receptor agonist | AGONIST | ChEMBL |
| OCTREOTIDE ACETATE | CHEMBL1200480 | Somatostatin receptor agonist | AGONIST | ChEMBL |
| ONZIGOLIDE | CHEMBL4650342 | Somatostatin receptor 2 agonist | AGONIST | ChEMBL |
| PALTUSOTINE | CHEMBL5267842 | Somatostatin receptor 2 agonist | AGONIST | ChEMBL |
| PASIREOTIDE | CHEMBL3349607 | Somatostatin receptor 2 agonist | AGONIST | ChEMBL |
| PASIREOTIDE DIASPARTATE | CHEMBL5314380 | Somatostatin receptor 2 agonist | AGONIST | ChEMBL |
1 to 10 of 14
See all 14 drugsTrials397
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07595237 | LUTETIUM OXODOTREOTIDE LU-177 | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07583563 | OCTREOTIDE | ClinicalTrials.gov | ||
| NCT07537010 | LUTETIUM OXODOTREOTIDE LU-177 | PHASE1 | ClinicalTrials.gov | |
| NCT07534371 | SOMATOSTATIN | ClinicalTrials.gov | ||
| NCT07460908 | OCTREOTIDE | ClinicalTrials.gov | ||
| NCT07316686 | LUTETIUM OXODOTREOTIDE LU-177 | PHASE1 | ClinicalTrials.gov | |
| NCT07304466 | SOMATOSTATIN | ClinicalTrials.gov | ||
| NCT07252401 | SOMATOSTATIN | ClinicalTrials.gov | ||
| NCT07229768 | LUTETIUM OXODOTREOTIDE LU-177 | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07189871 | LUTETIUM OXODOTREOTIDE LU-177 | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 397
See all 397 trialsNIH grants1,123
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SSTR2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 33 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 20 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 16 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 8 | 2025 |
| P30DK084567 | Mayo Center for Cell Signaling in Gastroenterology | 5 | 2025 |
| K12CA184746 | MSK Paul Calabresi Career Development Award for Clinical Oncology | 4 | 2025 |
| P01HL131478 | Stress-induced immune reprogramming in cardiovascular disease | 4 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 4 | 2025 |
| UL1TR002384 | Clinical and Translational Science Center | 4 | 2025 |
| ZIADK053200 | Diagnosis, Natural History, Management, tumor biology of Gastrinomas/PETs/Neuroendocrine tumors | 4 | 2025 |
1 to 10 of 1,123Source NIH's project files
See all 1,123 nih grantsPapers3,968
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SSTR2 receptor states and cellular metabolism modulate 177Lu-DOTATATE binding affinity. | EANM Innov | 2026 | 42819901 | PubTator, text mining | PubMed |
| Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy. | Pharmaceutics | 2026 | 42797334 | PubTator, text mining | PubMed |
| Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors. | J Neuroendocrinol | 2026 | 42785810 | PubTator, text mining | PubMed |
| Revisiting Alzheimer's Disease Through the Somatostatin-Mitochondria Axis. | Mol Neurobiol | 2026 | 42782557 | PubTator, text mining | PubMed |
| Hepatocyte nuclear factor 4 alpha defines a distinct subtype of lung carcinoid with therapeutic potential targeting somatostatin receptor 2. | Virchows Arch | 2026 | 42782345 | PubTator, text mining | PubMed |
| Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges. | Bioorg Chem | 2026 | 42762619 | PubTator, text mining | PubMed |
| Somatostatin and its type 2 receptor expression in the pregnant and laboring myometrium. | Am J Physiol Cell Physiol | 2026 | 42747790 | PubTator, text mining | PubMed |
| Intra-Islet Paracrine Regulation of Glucagon Secretion During Hypoglycemia, Euglycemia, and Hyperglycemia. | Ann N Y Acad Sci | 2026 | 42734243 | PubTator, text mining | PubMed |
| Patient-derived 3D organotypic co-cultures as a long-term ex vivo model for pleomorphic adenoma of the parotid gland. | Sci Rep | 2026 | 42733102 | PubTator, text mining | PubMed |
| Potential of sweetener substitutes to circumvent metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis risk: Integrating network toxicology and validation in vitro. | Food Chem Toxicol | 2026 | 42732869 | PubTator, text mining | PubMed |
1 to 10 of 3,968
See all 3,968 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6752
GET https://conductscience.org/api/genes/v1/6752/patents?page=2